###begin article-title 0
Loss of heterozygosity of TRIM3 in malignant gliomas
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 544 571 544 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tripartite motif protein 3 </italic>
###xml 572 577 572 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 611 634 611 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila brain tumor </italic>
###xml 635 639 635 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brat</italic>
###xml 727 733 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 538 543 <span type="species:ncbi:9606">Human</span>
Malignant gliomas are frequent primary brain tumors associated with poor prognosis and very limited response to conventional chemo- and radio-therapies. Besides sharing common growth features with other types of solid tumors, gliomas are highly invasive into adjacent brain tissue, which renders them particularly aggressive and their surgical resection inefficient. Therefore, insights into glioma formation are of fundamental interest in order to provide novel molecular targets for diagnostic purposes and potential anti-cancer drugs. Human Tripartite motif protein 3 (TRIM3) encodes a structural homolog of Drosophila brain tumor (brat) implicated in progenitor cell proliferation control and cancer stem cell suppression. TRIM3 is located within the loss of allelic heterozygosity (LOH) hotspot of chromosome segment 11p15.5, indicating a potential role in tumor suppression. ...
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 27 32 <span type="species:ncbi:9606">human</span>
Here we analyze 70 primary human gliomas of all types and grades and report somatic deletion mapping as well as single nucleotide polymorphism analysis together with quantitative real-time PCR of chromosome segment 11p15.5.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 208 214 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 57 62 <span type="species:ncbi:9606">human</span>
Our analysis identifies LOH in 17 cases (24%) of primary human glioma which defines a common 130 kb-wide interval within the TRIM3 locus as a minimal area of loss. We further detect altered genomic dosage of TRIM3 in two glioma cases with LOH at 11p15.5, indicating homozygous deletions of TRIM3.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
Loss of heterozygosity of chromosome segment 11p15.5 in malignant gliomas suggests TRIM3 as a candidate brain tumor suppressor gene.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1075 1076 1075 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1077 1078 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1257 1258 1257 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1259 1261 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 105 112 <span type="species:ncbi:9606">patient</span>
###xml 723 731 <span type="species:ncbi:9606">patients</span>
Malignant gliomas are brain tumors that represent devastating and difficult-to-treat cancers with a mean patient survival of 10 months. Although surgical interventions allow resection and improve local tumor control, the further course of the disease remains dominated by re-appearance of unscheduled cell proliferation and insidious infiltration of normal brain tissue. Especially glioblastomas appear notoriously resistant to therapy, which has been attributed to DNA-repair proficiency and deregulated molecular pathways [1,2]. More recently combined chemoradiotherapy of concomitant and adjuvant temozolomide and radiotherapy has been introduced which can lead to significant prolongation of survival, in particular in patients with an epigenetically silenced DNA repair gene [3]. However, the outcome remains poor. This therapeutic resistance has recently been attributed to tumor stem-like cells due to their unrestrained self-renewal capacity and the ability to maintain tumorigenic potential at the single cell level, thereby evading both resection and radiotherapy [4-7]. There is growing evidence that some brain cancers arise either from normal stem cells or from progenitor cells in which self-renewal pathways have become aberrantly activated [7-10].
###end p 11
###begin p 12
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brat</italic>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 177 188 177 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 459 464 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brat </italic>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Drosophila Brain tumor (brat) has been identified as a regulator of progenitor cell proliferation control and cancer stem cell suppression [11-18]. Brat is expressed throughout Drosophila brain development and exerts an essential gate-keeper function in the binary switch between self-renewal and differentiation of neural progenitor cells. Neural progenitor cells mutated for Brat are unable to differentiate but rather continue to proliferate, resulting in brat mutant cells that display characteristic features of cancer-like stem cells. The resulting brain tumor tissue is characterized by pleiomorphic cells, continued proliferation and chromosome instability, as evidenced by a variety of karyotypic abnormalities [19].
###end p 12
###begin p 13
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brat </italic>
###xml 94 121 94 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tripartite Motif Protein 2 </italic>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM2</italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM32</italic>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 436 442 436 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 69 74 <span type="species:ncbi:9606">human</span>
Homologues of brat have been recorded in various species, with three human homologues, namely Tripartite Motif Protein 2 (TRIM2), TRIM3, and TRIM32, located on chromosome 4q31.3, 11p15.5, and 9q33.1, respectively [20-23]. 11p15 represents the telomeric end of chromosome 11 which shows loss of allelic heterozygosity (LOH) in various types of tumors, indicating the presence of one or more tumor suppressor genes [24-27]. Homologues of TRIM3 are primarily expressed in brain and may function at the interface of proliferation and differentiation during the maturation of brain tissue [28-30]. Here we report refined deletion mapping of chromosome 11p15.5 in malignant gliomas.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Biopsies and DNA extraction
###end title 15
###begin p 16
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 837 838 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 319 326 <span type="species:ncbi:9606">patient</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
Tumor samples used in this study were obtained from 70 patients who underwent glioma resection at the University Hospital of Basel between 1996 and 2005. The collection of tumor samples has been approved by the Ethics Committee of Basel-Land and Basel-Stadt (EKBB). Informed consent has been obtained together with the patient's permission to conduct open brain surgery, consenting to the use of biopsies for anonymous scientific research. This procedure follows the present recommendations of the Swiss Academy of Medical Sciences as proposed in 2008 and is in compliance with the Helsinki Declaration. Tumors were classified according to the revised WHO classification of tumors of the nervous system [31], comprising 10 oligodendrogliomas grade II, 13 astrocytomas grades I to III, and 47 glioblastoma multiforme [see Additional file 1]. DNA was extracted from fresh frozen primary gliomas and peripheral blood mononuclear cells (PBMCs) derived from the same patients, as previously described [32,33]. Only material containing less than 30% residual amounts of non-neoplastic cells was considered for further analysis.
###end p 16
###begin title 17
STS- and SNP-based LOH analysis
###end title 17
###begin p 18
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 416 422 416 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1046 1052 1046 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Sequence tagged site (STS)-based LOH was performed essentially as described [32]. Briefly, DNA from 70 glioma specimens and PBMCs of the same patients was analysed for loss of heterozygosity by amplification of microsatellite sequences [32]. Primers for these sequences were obtained from Microsynth (Balgach, Switzerland). Fluorescence based LOH mapping was employed with DNA from all gliomas. D11S4905 (located in TRIM3 intron 2) and D11S1250 primers were FAM-labeled, D1S1318 and D11S1758 primers were HEX-labeled, and D11S1331 and D11S1997 primers were TET-labeled. PCR product size fractionation and quantification were performed on ABI Prism 310 Genetic Analyzer (PE Applied Biosystems, Foster City, CA, USA). The ratio of peak heights of both alleles was calculated for each tumor and PBMC DNA sample. For informative cases, allelic loss was scored if the ratio between tumor and PBMC DNA was more than 1.5 (1/0) or less than 0.66 (0/2). Single nucleotide polymorphism (SNP)-based LOH was performed with the following markers: rs11605881 (TRIM3 promoter), rs11607224 (exon1), rs1060067 (exon4) rs16913748 (exon6), rs11605141 (intron6), rs13343175 (intron7), rs3830325 (intron9), rs2306897 (exon10) and rs2723636 (exon13). SNPs were visualized on an ABI Prism 310 Genetic Analyzer (PE Applied Biosystems, Foster City, CA, USA).
###end p 18
###begin title 19
Quantitative real-time PCR
###end title 19
###begin p 20
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 116 120 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 222 224 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 275 280 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 394 400 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
Classification of the genetic status of TRIM3 was performed by quantitative real-time-PCR using the TaqMan ABI Prism(R) 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA) as previously described [34]. Gene-specific primers for the reference-control GAPDH, which is located on chromosome 12p13.3, as well as primers for Intron1, Exon 3, Intron 6, Intron 11 and cDNA of TRIM3 were used as follows:
###end p 20
###begin p 21
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
For GAPDH:
###end p 21
###begin p 22
5'-AATGGGACTGAGGCTCCAC (sense),
###end p 22
###begin p 23
5'-TTATGGGAAAGCCAGTCCCC (antisense).
###end p 23
###begin p 24
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 Intron 1:
###end p 24
###begin p 25
5'-CCCCAAGGGTGCGTTTGTATT (sense),
###end p 25
###begin p 26
5'-TGCTCTCACGGACATGGACA (antisense).
###end p 26
###begin p 27
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 Exon 3:
###end p 27
###begin p 28
5'-GCAGTTCCTGGTATGCAGCAT (sense),
###end p 28
###begin p 29
5'-TGCAGGCAAGGAAGAACCTT (antisense).
###end p 29
###begin p 30
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 Intron 6:
###end p 30
###begin p 31
5'-GGGCCAAACAGAAGGTGTGT (sense),
###end p 31
###begin p 32
5'-GGCATGTCAGGAGGCAGAAT (antisense).
###end p 32
###begin p 33
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 Intron 11:
###end p 33
###begin p 34
5'-AGGCAGTAGGGCACATGGAT (sense),
###end p 34
###begin p 35
5'-GAGAACCCCCACCCAGATCT (antisense).
###end p 35
###begin p 36
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 cDNA Exons 7/8:
###end p 36
###begin p 37
5'-GGCGGCAAACGAAAGGA (sense),
###end p 37
###begin p 38
5'-CCTTCCACGACTGCCAACA (antisense).
###end p 38
###begin p 39
Gene-specific double-dye FAM-TAMRA labelled oligomeric probes were:
###end p 39
###begin p 40
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
For GAPDH: FAM-ATCCAAGACTGGCTCCTCCCTGCTG-TAMRA.
###end p 40
###begin p 41
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 Intron 1: FAM-CCCACAGCCGCTCCGACCCA-TAMRA.
###end p 41
###begin p 42
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 Exon 3: FAM-TGCCTGGATCGGTACCAGTGCCC-TAMRA.
###end p 42
###begin p 43
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 Intron 6: FAM-CACCAGCTCCCCATTCCCCA-TAMRA.
###end p 43
###begin p 44
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 Intron 11: FAM-CAGCTACAGCCCAAATCTGCTTCATAGGCTT-TAMRA.
###end p 44
###begin p 45
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
For TRIM3 cDNA: FAM-AACCCAATTGAGGATGAGCTCGTCTTCC-TAMRA.
###end p 45
###begin p 46
###xml 76 80 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 434 435 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
###xml 455 461 453 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GADPH </italic>
###xml 498 500 496 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 704 706 702 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 758 760 752 754 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 801 803 795 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 825 827 819 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 845 846 835 836 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
###xml 926 932 916 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 966 968 952 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 975 977 961 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 992 994 978 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1011 1013 993 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1107 1109 1083 1085 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1281 1283 1251 1253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
PCR conditions, primers and probe design were assessed by the Primer Express(R) program (PE Applied Biosystems, Foster City, CA, USA). Final primer concentration was 200 nM and fluorescent oligomeric probe concentration was 50 nM. Fifty ng genomic DNA derived from primary tumor tissue was taken as template. Genomic DNA amounts between normal and neoplastic tissues were standardized by subtracting the respective threshold cycles (Cts) obtained for the GADPH gene. In this approach the variable Ct is defined as the fractional cycle number crossing a fixed threshold of fluorescence that has been generated by cleavage of the probe due to polymerase driven exonucleolytic activity. Differences in the Ct values between two genes were referred to the DeltaCt value. After normalization of the tumor Ct values with the PBMC Ct values, the DeltaCtvalues and the relative copy number of Introns1, 6 and 11, as well as Exon 3 of TRIM3 were calculated as follows: DeltaCt (X) = Ct (reference) - Ct (X). Thus, DeltaCt values of 0 +/- 0.3 [-0.3;+0.3] indicated retention of both alleles (diploidy = 2n) and DeltaCt values of -1 +/- 0.3 [-0.7;-1.3] indicated loss of one allele (haploidy = n). Due to the frequent contamination of tumor biopsy DNA by that of invaded normal tissue, DeltaCt values of < -1.30 were accounted as indicative for homozygous deletions. All analyses of tumor samples were performed in triplicate in parallel with PBMC DNA, and data indicating homozygous deletions resulted from two independent experiments.
###end p 46
###begin title 47
Results
###end title 47
###begin title 48
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 7 12 <span type="species:ncbi:9606">human</span>
LOH in human gliomas reveals a 130 kb minimally lost area uncovering TRIM3
###end title 48
###begin p 49
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 451 457 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 516 521 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM5</italic>
###xml 523 528 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM6</italic>
###xml 530 536 530 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM22</italic>
###xml 542 549 542 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM34 </italic>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASCL2 </italic>
###xml 590 595 590 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASCL3</italic>
###xml 630 641 630 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 654 668 654 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">achaete-scute </italic>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 836 837 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1150 1156 1150 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1280 1282 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 888 893 <span type="species:ncbi:9606">human</span>
Initial studies had identified an approximately 21 centiMorgan region on 11p15.5-pter that showed frequent loss of heterozygosity in malignant gliomas [35]. This region has been refined to 7 megabases (Mb) [24], spanning the region 11p15.4-5 between microsatellite markers (also called STS) D11S922 and D11S1250 (Fig. 1). Several genes are contained within this interval that might be involved in brain development and/or tumor suppression, including TRIM3 and a cluster of genes encoding the more distantly related TRIM5, TRIM6, TRIM22, and TRIM34 genes. This area also contains ASCL2 and ASCL3. Both genes are homologues of the Drosophila genes of the achaete-scute (ASC) complex that promote cells to develop a neural fate [36], which therefore may represent additional candidate brain tumor suppressors encoded by this region (Fig. 1). We performed loss of heterozygosity analysis on human brain tumor samples representing 70 primary gliomas of varying histology and grades including 13 astrocytomas (AS) WHO grades I to III, 10 oligodendrogliomas (OG) WHO grade II, and 47 glioblastomas (GBM). We focused our LOH analysis on the region spanning TRIM3 by using 6 microsatellite markers in addition to the ones that had been used earlier to determine the minimal area of loss [24].
###end p 49
###begin p 50
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 0 115 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Deletion mapping of chromosomal region 11p15.5 in human primary gliomas defines a 130 kb-wide area containing <italic>TRIM3</italic></bold>
###xml 117 118 117 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM5</italic>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM6</italic>
###xml 212 218 212 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM22</italic>
###xml 224 231 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM34 </italic>
###xml 249 255 249 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASCL2 </italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASCL3</italic>
###xml 955 961 955 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1068 1069 1068 1069 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 50 55 <span type="species:ncbi:9606">human</span>
Deletion mapping of chromosomal region 11p15.5 in human primary gliomas defines a 130 kb-wide area containing TRIM3. A. The 11p15.5 chromosomal region highlighting TRIM3, the more distantly related TRIM5, TRIM6, TRIM22, and TRIM34 genes, as well as ASCL2 and ASCL3; arrows indicate transcription orientations. Middle panel: somatic deletion of the 11p15.5 region in glioma. Tumor histology, grades and numbers are indicated on the left. Allelic retention, allelic loss and non-informative data are represented by open, closed and grey circles, respectively. Minimal and maximal extensions of allelic loss are shown with filled and hatched grey areas, respectively. The 11p15 microsatellite markers/sequence tag sites (STS) used are indicated (D11S1318, D11S1758, D11S1997, D11S4905, D11S1331, D11S1250). Alignment of LOH data delimits a minimal area of 130 kb showing LOH common to all 10 tumors between markers D11S1997 and D11S4905 which identifies the TRIM3 locus. GBMs displaying complete loss of the central region were not tested for D11S1318 and D11S1250 (ND). B. Informative LOH data with marker D11S4905 comparing normal (N) with tumor (T) DNA for brain tumors OGII 040, ASIII 098, ASII 141, GBM 157, GBM 164. Abbreviations: GBM, Glioblastoma multiforme; AS, astrocytoma; OG, oligodendroglioma; RET, retention; LOH, loss of heterozygosity; ND, not determined; NI, non-informative.
###end p 50
###begin p 51
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 605 606 605 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1273 1279 1273 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1291 1292 1291 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1357 1363 1357 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
Among the 70 primary tumor samples tested, 17 out of 70 (24%) showed LOH of at least one marker in this region. Heterozygous deletions included 12 GBM out of 47 analysed (25%) consistent with the 11p15.5 deletion frequency previously described in GBM [24]. Further, one OG grade II out of 10 (10%) showed 11p15.5 allelic loss. No allelic loss was detected in AS grade I (0/3), while heterozygous deletions were observed in 2 AS grade II out of 7 (28%) as well as in 2 AS grade III out of 3 (67%), suggesting a graded escalation of 11p15.5 deletion frequency with tumor grading in AS (see Table 1 and Fig. 1). Some of these heterozygous deletions, including OGII 040, ASII 141, and GBM 157, covered the complete region 11p15 (D11S1318, D11S1758, D11S1997, D11S4905, D11S1331, D11S1250). At the telomeric side, GBM tumor 167 showed the longest retention proximally extending to STS marker D11S1997, whereas ASII tumor 031 had the most distal extension of retention to STS marker D11S4905. Therefore, alignment of our LOH data with the physical map of the 11p telomeric region delimited a minimal area of loss common to all of these tumors between markers D11S1997 and D11S4905. This interval reduced the minimal area of loss from 7 Mb to only 130 kilobases (kb) covering the TRIM3 locus (Fig. 1), and also pointed to potential breakpoint mutations within the TRIM3 gene between Exons 3-13.
###end p 51
###begin p 52
11p15.5 LOH frequencies among glioma subsets
###end p 52
###begin p 53
Abbreviations: OG, oligodendroglioma; AS, astrocytoma; GBM, Glioblastoma multiforme; I-III, WHO grade; LOH, loss of heterozygosity.
###end p 53
###begin title 54
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
Genomic dosage alterations of TRIM3 in malignant gliomas
###end title 54
###begin p 55
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
In order to refine somatic deletion mapping and to delimit the minimal area of loss in more detail, we used single nucleotide polymorphic (SNP) markers located within the TRIM3 genomic area to further investigate a selection of tumor samples. For further analysis, we selected those tumors that were indicative for loss or at least partial loss of the analysed region at 11p15, namely GBMs 149, 157, 164, 167, and 211, as well as ASII 031, ASIII 023, and ASIII 098 (Fig. 2A).
###end p 55
###begin p 56
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 0 128 0 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SNP-based somatic deletion mapping of chromosomal region 11p15.5 identifies potential breakpoint mutations within the <italic>TRIM3 </italic>gene</bold>
###xml 130 131 130 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 984 990 984 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1221 1227 1221 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1233 1234 1233 1234 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1420 1426 1420 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
SNP-based somatic deletion mapping of chromosomal region 11p15.5 identifies potential breakpoint mutations within the TRIM3 gene. A. Superimposition of single nucleotide polymorphism (SNP) and sequence tag site (STS)-based LOH data. (Note that compared to Fig. 1, the map has been inverted to comply with the 5'-3' transcription orientation of the TRIM3 gene). STS markers (D11S series) are indicated on the top; tumor histology, grades and numbers are indicated on the left. Allelic retention, allelic loss and non-informative data are represented by open, closed and grey circles, respectively. Minimal and maximal extension of STS-based areas of allelic loss described in Fig. 1, are shown with filled and hatched grey areas, respectively. Areas of local allelic retention defined by SNP analysis within segments of allelic loss defined by STS analysis are framed by open rectangles. SNP and STS data, as well as SNP markers (rs series) used are related to a structural map of the TRIM3 gene with its coding regions shown in black (bottom). Thus, SNP-based allelic retention of short sections within the areas of LOH in primary gliomas ASIII 098, GBM 157, and GBM 164 suggest potential homozygous deletions within the TRIM3 gene. B. SNP bi-allelism in primary tumors with 11p15.5 allelic loss. Sequence electrophoretograms of genomic DNA extracted from primary tumor samples amplified at indicated SNP markers of the TRIM3 gene area; peak color codes: green (A), blue (C), black (G), red (T). Abbreviations: GBM, Glioblastoma multiforme; AS, astrocytoma; OG, oligodendroglioma; RET, retention; LOH, loss of heterozygosity; NI, non-informative.
###end p 56
###begin p 57
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 516 522 516 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 581 587 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 598 599 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 712 718 712 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 997 1003 997 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1097 1103 1097 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1153 1154 1153 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Among the ten SNPs initially selected, six turned out to be non-informative in all analyzed tumors whereas four SNPs, namely rs11605881, rs11607224, rs16913748, rs11605141, displayed loss of heterozygosity or allelic retention in those tumors selected for further analysis (Fig. 2). Thus, we observed allelic retention of both parental alleles of SNPs rs11605881, rs16913748, and rs11605141 in primary tumors ASII 031 and GBM 211, respectively. These data displaced the centromeric rim of the minimally lost area of TRIM3 from STS D11S4905 to SNP rs11605141 but still targeted the TRIM3 gene (Fig. 2). In addition, in those cases where we observed STS-based loss of heterozygosity extending on both sides of the TRIM3 gene (ASIII 098, GBM 157 and GBM 164), the detected area of LOH was locally interrupted by short sections with allelic retention at SNPs rs11605881 and rs11607224. Indeed, tumors ASIII 098 and GBM 164 showed heterozygosity at SNP markers rs11605881 and rs11607224 located in the TRIM3 promoter and in exon1, respectively, whereas analysis of markers rs16913748 and rs11605141 of TRIM3 intron 6 revealed heterozygosity in GBM 157 (Fig. 2).
###end p 57
###begin p 58
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 447 453 447 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 545 551 545 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 748 754 748 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 1031 1036 1031 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 917 925 <span type="species:ncbi:9606">patients</span>
Allelic retention within a chromosomal interval displaying LOH has been interpreted as a potential site of homozygous deletion, where retention seems to result from the amplification of wildtype DNA deriving from non-neoplastic cells present in the tumor biopsy [37]. Thus, SNP-based allelic retention of short sections within the areas of LOH in primary gliomas ASIII 098, GBM 157, and GBM 164 indicated potential homozygous deletions within the TRIM3 gene. In order to investigate this possibility, we targeted four equidistant regions of the TRIM3 gene, including the two areas of possible homozygous loss in the three primary tumor samples ASIII 098, GBM 157 and GBM 164 by quantitative real-time PCR (Q-PCR). Analysis of the genetic status of TRIM3 in ASIII 098, GBM 157, and GBM 164 was assayed on DNA extracted from both the primary gliomas and peripheral blood mononuclear cells (PBMCs) derived from the same patients by Q-PCR of the reference-control gene GAPDH, as well as for Intron1, Exon 3, Intron 6, and Intron 11 of TRIM3, respectively (see Methods).
###end p 58
###begin p 59
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 157 159 153 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 275 290 269 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 intron 1 </italic>
###xml 352 353 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 434 449 428 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 intron 6 </italic>
###xml 456 458 446 448 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 479 489 467 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">intron 11 </italic>
###xml 496 498 480 482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 615 616 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 712 718 694 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 747 749 725 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 858 859 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1031 1037 1009 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 889 894 <span type="species:ncbi:9606">human</span>
In ASIII 098, tumor genomic dosage in TRIM3 intron 1, at the site between SNP markers rs11605881 and rs11607224 indicated DNA levels below haploidy of DeltaCt = -1.98 +/- 0.40 (for calculation details, see Methods). These results signified a homozygous deletion encompassing TRIM3 intron 1 as already indicated by data of SNP rs11605881 analysis (Fig. 3). Similarly, Q-PCR analysis of GBM 157 indicated DNA levels below haploidy from TRIM3 intron 6 (DeltaCt = -1.59 +/- 0.20) to intron 11 (DeltaCt = -1.43 +/- 0.20), signifying homozygous deletion as already indicated by SNPs markers rs1693748 and rs1605141 (Fig. 3). In contrast, genomic dosage of primary tumor GBM 164 indicated continuous diploidy along the TRIM3 gene as exemplified by DeltaCt values between -0.30 and +0.30 of four Q-PCR markers covering intron 1, exon 3, intron 6 and intron 11 (Fig. 3). Thus, among the 10 primary human glioma identified with allelic loss at 11p15.5, Q-PCR analysis of ASIII 098 and GBM 157 (20%) indicated homozygous deletions within the TRIM3 gene.
###end p 59
###begin p 60
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Altered genomic dosage of <italic>TRIM3 </italic>suggests homozygous deletions in human primary gliomas</bold>
###xml 88 89 88 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 247 249 243 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 372 374 360 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 439 445 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 485 486 473 474 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 649 655 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 65 70 <span type="species:ncbi:9606">human</span>
Altered genomic dosage of TRIM3 suggests homozygous deletions in human primary gliomas. A. Genomic dosage of the TRIM3 gene area of ASIII 098, GBM 157, and GBM 164 as determined by quantitative real-time PCR. Light grey background indicates DeltaCt cut-offs for diploidy (2n = 0 +/- 0.3) and haploidy (n = -1 +/- 0.3) for each primary tumor sample; grey bars depict DeltaCt values of amplified tumor DNA related to a structural map of the TRIM3 gene with coding regions shown in black B. Mapping of indicated homozygous deletions within the TRIM3 gene. STS-based and SNP-based compilation of Q-PCR data is shown in relation to structural map of the TRIM3 gene with coding regions shown in black. Tumor histology, grades and numbers are indicated on the left. STS-based (D11S series) allelic loss and non-informative data are represented by closed and grey circles, respectively. Areas of local allelic retention defined by SNP analysis (rs series) within segments of allelic loss defined by STS analysis are framed by open rectangles. Copy number deduced from Q-PCR data are indicated; minimal and maximal extension of allelic loss' are shown with filled and hatched grey areas, respectively; areas of homozygous loss are shown in black. Q-PCR data indicate homozygous deletions in primary tumors ASIII 098 and GBM 157. Abbreviations: GBM, Glioblastoma multiforme; AS, astrocytoma; OG, oligodendroglioma; RET, retention; LOH, loss of heterozygosity; NI, non-informative; Q-PCR, quantitative real-time polymerase chain reaction.
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 422 431 422 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top-down </italic>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 561 571 561 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom-up </italic>
###xml 651 662 651 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 730 736 730 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 486 491 <span type="species:ncbi:9606">human</span>
In cancer research, conventional strategies of somatic deletion mapping rely on the detection of frequent sites of larger DNA alterations. Accordingly, allelic loss of heterozygosity analysis of tumor DNA facilitates the identification and localization of a minimally lost area correlating with candidate tumor suppressor gene loci that might be involved in the tumorigenic process [38]. In contrast to these conventional top-down strategies, we carried out somatic deletion mapping on human glioma DNA focusing on the TRIM3 locus. We opted for this unorthodox bottom-up strategy as a result of significant structural homologies between TRIM3 and the Drosophila brain tumor suppressor Brat [19], as well as owing to the fact that TRIM3 is located on chromosome segment 11p15.5.
###end p 62
###begin p 63
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
Previous analyses demonstrated that chromosome segment 11p15 contains a region of frequent loss of allelic heterozygosity in various adult tumors including those of the brain, lung, breast, ovary, esophagus, stomach, as well as others [27,35,39-44]. The frequency of LOH in this region and its apparent correlation with metastatic tumor spread suggests that this chromosome segment may represent a hotspot containing one or more tumor suppressor gene(s).
###end p 63
###begin p 64
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 243 249 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASCL2 </italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASCL3</italic>
###xml 284 309 284 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila achaete-scute </italic>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 356 379 356 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila brain tumor </italic>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
In the case of brain tumors, a previous LOH study delimited the minimal area of loss to a final 7 Mb-wide genomic interval spanning several genes with a potential role in both developing and neoplastic brain tissue [24]. Among those genes are ASCL2 and ASCL3, mammalian homologues of Drosophila achaete-scute complex [36], as well as TRIM3, a homologue of Drosophila brain tumor involved in progenitor cell proliferation control and cancer stem cell suppression [19], and a cluster of more distantly related TRIM genes (see Figure 1).
###end p 64
###begin p 65
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Compared to the earlier study by Schiebe et al. [24], we analyzed an equivalent number of GBMs (n = 47 vs. n = 50), as well as brain tumors that are distinct in origin, i.e. OG (n = 10) and AS (n = 13). By focusing on GBM only (see Table 1), our data revealed similar deletion frequencies (25% vs. 28%) to those previously obtained in GBM [24]. Interestingly, our deletion analysis revealed increased frequencies in AS of higher grade, which might indicate a possible association of 11p15.5 allelic loss with tumor progression. However, this conclusion needs to be strengthened by the analysis of a larger number of AS.
###end p 65
###begin p 66
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASCL2 </italic>
###xml 192 198 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASCL3 </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM </italic>
###xml 390 396 390 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 464 470 464 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
Furthermore, as compared to the 7 Mb region previously described [24], our somatic deletion mapping analysis delimited a 130 kb-wide minimal area of loss. Thus, our results rule out ASCL2 and ASCL3 and the more distantly related TRIM genes as potential glioma tumor suppressors within the genomic region analyzed. Significantly, the 130 kb-wide minimal area of loss not only identified the TRIM3 locus, but also indicated potential breakpoint mutations within the TRIM3 gene.
###end p 66
###begin p 67
###xml 378 394 378 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14ARF/p16INK4a </italic>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 526 532 526 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3</italic>
###xml 920 931 920 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 449 454 <span type="species:ncbi:9606">human</span>
###xml 704 709 <span type="species:ncbi:9606">human</span>
We further substantiated our LOH data by single nucleotide polymorphism analysis together with quantitative real-time PCR. Previous studies showed that Q-PCR can identify micro-deletions providing a reliable approach for a direct and specific determination of the ploidy status within defined genetic loci. This approach led to the identification of homozygous deletions of the p14ARF/p16INK4a tumor suppressor locus which is frequently affected in human gliomas [34]. Significantly, we detected genomic dosage alterations of TRIM3 in two glioma cases with LOH at 11p15.5, indicating homozygous deletions of TRIM3. Our LOH and Q-PCR data therefore suggest that TRIM3 may act as a tumor suppressor in the human brain. However, in vitro and mammalian in vivo loss- as well- as gain-of function analyses are required to determine the function of TRIM3 in detail. It will be interesting to see whether TRIM3, similar to its Drosophila homologue Brain tumor, is involved in the regulation of progenitor cell proliferation control and brain tumor suppression.
###end p 67
###begin title 68
Conclusion
###end title 68
###begin p 69
###xml 186 192 186 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 255 261 255 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIM3 </italic>
###xml 89 94 <span type="species:ncbi:9606">human</span>
Our analysis identifies loss of allelic heterozygosity at 11p15.5 in 17 cases of primary human glioma and defines a common 130 kb-wide interval as a minimal area of loss that covers the TRIM3 locus. In two glioma cases with LOH, altered genomic dosage of TRIM3 indicates homozygous deletions. Together, these data suggest TRIM3 as a 11p15.5 candidate brain tumor suppressor gene. Further investigation will be needed to elucidate the biological function of TRIM3 and its precise role in brain tumor suppression.
###end p 69
###begin title 70
Abbreviations
###end title 70
###begin p 71
GBM: Glioblastoma multiforme; AS: astrocytoma; OG: oligodendroglioma; RET: retention; LOH: loss of heterozygosity; ND: not determined; NI: non-informative; Q-PCR: quantitative real-time polymerase chain reaction.
###end p 71
###begin title 72
Competing interests
###end title 72
###begin p 73
The authors declare that they have no competing interests.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
FH conceived, and FH, JLB and AM designed the study; US, ET, and BD acquired the data; FH, JLB and AM analyzed and interpreted the data; FH and JLB wrote the manuscript. All authors read and approved the final manuscript.
###end p 75
###begin title 76
Pre-publication history
###end title 76
###begin p 77
The pre-publication history for this paper can be accessed here:
###end p 77
###begin p 78

###end p 78
###begin title 79
Supplementary Material
###end title 79
###begin title 80
Additional file 1
###end title 80
###begin p 81
###xml 0 100 0 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LOH data for all gliomas investigated. The data provided represent all 70 glioma cases investigated.</bold>
LOH data for all gliomas investigated. The data provided represent all 70 glioma cases investigated.
###end p 81
###begin p 82
Click here for file
###end p 82
###begin title 83
Acknowledgements
###end title 83
###begin p 84
We thank Mihai Ionescu and Heinrich Reichert for comments on earlier versions of the manuscript, and Heinrich Reichert for support. This work was funded by grants from the Swiss Cancer League (OCS-01613-12-2004) and the Krebsliga beider Basel (No. 7-2004) (to FH and AM).
###end p 84
###begin article-title 85
###xml 44 50 <span type="species:ncbi:9606">humans</span>
###xml 55 61 <span type="species:ncbi:10090">murine</span>
Genes and pathways driving glioblastomas in humans and murine disease models
###end article-title 85
###begin article-title 86
###xml 47 52 <span type="species:ncbi:9606">human</span>
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
###end article-title 86
###begin article-title 87
Chemoradiotherapy in malignant glioma: Standard of care and future directions
###end article-title 87
###begin article-title 88
Self-renewal and solid tumor stem cells
###end article-title 88
###begin article-title 89
Neural stem cells and origin of gliomas
###end article-title 89
###begin article-title 90
Brain tumor stem cells
###end article-title 90
###begin article-title 91
Glioma stem cells: A midterm exam
###end article-title 91
###begin article-title 92
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human brain tumour initiating cells
###end article-title 92
###begin article-title 93
Radial glia cells are candidate stem cells of ependymoma
###end article-title 93
###begin article-title 94
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
###end article-title 94
###begin article-title 95
###xml 46 69 46 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila brain tumor </italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brat</italic>
Mutations in the beta-propeller domain of the Drosophila brain tumor (brat) protein induce neoplasm in the larval brain
###end article-title 95
###begin article-title 96
###xml 53 63 53 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
Transcriptional signature of an adult brain tumor in Drosophila
###end article-title 96
###begin article-title 97
###xml 70 93 70 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster</italic>
###xml 70 93 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster
###end article-title 97
###begin article-title 98
###xml 4 16 4 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brain tumor </italic>
###xml 110 120 110 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
The brain tumor gene negatively regulates neural progenitor cell proliferation in the larval central brain of Drosophila
###end article-title 98
###begin article-title 99
Brat is a Miranda cargo protein that promotes neuronal differentiation and inhibits neuroblast self-renewal
###end article-title 99
###begin article-title 100
###xml 78 89 78 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
Asymmetric segregation of the tumor suppressor Brat regulates self-renewal in Drosophila neural stem cells
###end article-title 100
###begin article-title 101
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
Drosophila brain tumor metastases express both neuronal and glial cell type markers
###end article-title 101
###begin article-title 102
###xml 87 97 87 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
The tumor suppressors Brat and Numb regulate transit-amplifying neuroblast lineages in Drosophila
###end article-title 102
###begin article-title 103
Asymmetric cell division in development and cancer
###end article-title 103
###begin article-title 104
The tripartite motif family identifies cell compartments
###end article-title 104
###begin article-title 105
###xml 120 125 <span type="species:ncbi:9606">human</span>
Cloning and characterization of a gene (RNF22) encoding a novel brain expressed ring finger protein (BERP) that maps to human chromosome 11p15.5
###end article-title 105
###begin article-title 106
Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene
###end article-title 106
###begin article-title 107
Genomic analysis of the TRIM family reveals two groups of genes with distinct evolutionary properties
###end article-title 107
###begin article-title 108
Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas
###end article-title 108
###begin article-title 109
###xml 55 60 <span type="species:ncbi:9606">human</span>
Loss of methylation at chromosome 11p15.5 is common in human adult tumors
###end article-title 109
###begin article-title 110
Loss of heterozygosity on chromosome 11 in esophageal squamous cell carcinomas
###end article-title 110
###begin article-title 111
###xml 55 60 <span type="species:ncbi:9606">human</span>
CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer
###end article-title 111
###begin article-title 112
Cloning and characterization of a novel RING finger protein that interacts with class V myosins
###end article-title 112
###begin article-title 113
BERP, a novel ring finger protein, binds to alpha-actinin-4
###end article-title 113
###begin article-title 114
The molluscan RING-finger protein L-TRIM is essential for neuronal outgrowth
###end article-title 114
###begin article-title 115
The WHO classification of tumors of the nervous system
###end article-title 115
###begin article-title 116
New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26
###end article-title 116
###begin article-title 117
Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas
###end article-title 117
###begin article-title 118
###xml 141 146 <span type="species:ncbi:9606">human</span>
Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas
###end article-title 118
###begin article-title 119
Loss of heterozygosity at 11p15 in malignant glioma
###end article-title 119
###begin article-title 120
Patterning of the Drosophila nervous system: the achaete-scute gene complex
###end article-title 120
###begin article-title 121
###xml 40 45 <span type="species:ncbi:9606">human</span>
Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction
###end article-title 121
###begin article-title 122
Genetic pathways to primary and secondary glioblastoma
###end article-title 122
###begin article-title 123
Loss of heterozygosity for chromosome 11 in adenocarcinoma of the stomach
###end article-title 123
###begin article-title 124
###xml 30 35 <span type="species:ncbi:9606">human</span>
Chromosome 11p15 deletions in human malignant astrocytomas and primitive neuroectodermal tumors
###end article-title 124
###begin article-title 125
###xml 43 48 <span type="species:ncbi:9606">human</span>
Multiple mechanisms downregulate CDKN1C in human bladder cancer
###end article-title 125
###begin article-title 126
A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas
###end article-title 126
###begin article-title 127
Identification of a new commonly deleted region within a 2-cM interval of chromosome 11p11 in breast cancers
###end article-title 127
###begin article-title 128
Transcript map and complete genomic sequence for the 310 kb region of minimal allele loss on chromosome segment 11p15.5 in non-small-cell lung cancer
###end article-title 128

